Results 51 to 60 of about 303,312 (346)

JUVENILE CHRONIC ARTHRITIS WITH EYE LESION

Научно-практическая ревматология, 2002
A bstract. Objective, to describe a series of pts with JRA/JCA and uveitis. Material and methods. The study included 81 pts with JRA and uveitis. There were 68 girls-84%, 13 boys-16%.
S O Salugina, N N Kuzmina, A L Speransky, I A Guseva, S. M. Ivanova   +4 more
doaj   +1 more source

Biologic therapy of rheumatoid arthritis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2009
Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions.
Damjanov Nemanja, Vojinović Jelena
doaj   +1 more source

Glyco-biomarkers: Potential determinants of cellular physiology and pathology [PDF]

, 2008
Once dismissed as just the icing on the cake, sugar molecules are emerging as vital components in life’s intricate machinery. Our understanding of their function within the context of the proteins and lipids to which they are attached has matured rapidly,
Alavi, A, Axford, JS
core   +2 more sources

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide

São Paulo Medical Journal
CONTEXT: Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy. CASE REPORT: We followed the clinical course of 4 patients (2 male, 2 female) aged 9.1-17.8 years (mean of 14.5 years) with polyarticular onset of ...
Tania Caroline Monteiro de Castro, Maria Teresa Terreri, Claudio Len, Maria Odete Esteves Hilário   +3 more
doaj   +1 more source

Experience of use of the anti-cytokine drug adalimumab in children with polyarticular seronegative junior arthritis living in the Samara region

Лечащий Врач, 2023
Background. Juvenile idiopathic arthritis is the most common rheumatic disease in childhood. Adalimumab is the drug of choice for polyarthritis, HLA-B27-associated arthritis, psoriatic arthritis, as well as for the association of arthritis with ...
S. V. Plakhotnikova, G. V. Santalova, Yu. V. Serezhkina, O. V. Sluzhaeva   +3 more
doaj   +1 more source

The effectiveness of a multidisciplinary foot care program for children and adolescents with juvenile idiopathic arthritis: an exploratory trial [PDF]

, 2013
Objectives: To evaluate the effectiveness of multidisciplinary foot-care, and to evaluate the methodological considerations of a trial of multidisciplinary care in juvenile idiopathic arthritis. Design: Exploratory randomised controlled trial.
Brandon, Mhairi, Friel, Lorraine, Gardner-Medwin, Janet, Hendry, Gordon, Lorgelly, Paula K., Sturrock, Roger D., Turner, Deborah, Watt, Gordon, Woodburn, James   +8 more
core   +1 more source

Performance Characteristics of Anti‐Collagen II Antibodies in Relapsing Polychondritis and Related Diseases: Prospective Analysis, Systematic Review, and Meta‐Analysis

Arthritis Care &Research, Accepted Article.
Background Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti‐collagen II (anti‐Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick, Marcela A. Ferrada, Alice Fike, Kaitlin A. Quinn, Benjamin A. Turturice, Casey Stein, Peter C Grayson   +6 more
wiley   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi, Alten, Askling, Axford, Barrick, Bean, Bekkelund, Bongartz, Burmester, Burmester, Capellino, Cheng, Chiu, Chou, Combs, De Almeida, De Rycke, Detrait, Diamond, Doran, Doran, Emmer, Fayed, Feldmann, Firestein, Franklyn A. Howe, Germano, Gregersen, Gussew, Hamed, Harris, Ho, Hull, Hunter, Inan, Jacobs, Kaltsonoudis, Keane, Keystone, King, Klareskog, Lauvsnes, Lee, Leombruno, Lipsky, Listing, MacGregor, Mahdi, Malaviya, Markenson, McInnes, Medeiros, Mellor, Meseguer, Mikuls, Morris, Nadeau, Ni Mhuircheartaigh, Nicholas R. Fuggle, Nidhi Sofat, Nishioku, Norheim, O'Callaghan, Ogawa, Panayi, Parks, Rachel L. Allen, Ramiro, Rech, Rosenblum, Salliot, Salmon-Ceron, Scher, Schoels, Schweinhardt, Scott, Senaldi, Serrats, Skelly, Smolen, Sokka, Steens, Strangfeld, Symmons, Taylor, Teeling, Thomson, Tracey, Tubach, Upadhyay, van der Woude, van Heemst, van Vollenhoven, Vincent, Wallis, Wartolowska, Wegner, Wellcome Trust Case Control Consortium., Wendler, Weyand, Wolfe, Woolf, Zivadinov   +102 more
core   +2 more sources

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source